Some insomnia medicines block a brain signal called orexin. A new narcolepsy medicine turns that same signal’s receptor on. Both can be right, because the two conditions involve opposite problems in the same system.
Part 11 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Orexin, also called hypocretin, helps the brain hold a stable waking state. It is made by a small group of cells and works through two receptors, OX1R and OX2R.
- Three insomnia medicines block both orexin receptors to reduce wake drive. A new narcolepsy medicine, oveporexton, activates one of those receptors instead.
- Narcolepsy type 1 is a specific, well-documented condition in which the cells that make orexin have been lost. That is different from ordinary tiredness or ordinary insomnia.
- FDA approval, DEA scheduling, and pharmacy availability are three separate steps. Oveporexton was FDA-approved but was not yet legally available at the time this article was written.
- A proposal to loosen the controlled-substance schedule for the three insomnia drugs was not a final rule as of this writing.
- No blood, urine, or saliva test can measure orexin activity in a living brain circuit well enough to diagnose fatigue or choose a medicine.
The short answer
Orexin is a signal made by a small group of cells deep in the brain, in a region called the lateral hypothalamus. Those cells send connections widely across the brain, and the system’s main job is to help keep wakefulness stable, holding the line between being awake, being in regular sleep, and being in REM sleep.
Orexin acts on two receptors, OX1R and OX2R. Location matters here just as much as it does with other brain chemicals in this series. OX2R is especially important for stable wakefulness. OX1R also plays a role in arousal, stress, and reward circuits. That is not a one-receptor, one-feeling system.
Three U.S. insomnia medicines, suvorexant, lemborexant, and daridorexant, block both receptors at once.345 Blocking orexin lowers wake drive, which can make it easier to fall or stay asleep. A different medicine, oveporexton, does the opposite: it selectively activates OX2R. It was approved for adults with narcolepsy type 1, a condition in which the brain’s orexin-making cells have been lost, so the receptor is present but has little of its own signal left to respond to.19
These opposite actions make sense once you see that they are solving opposite problems. Blocking orexin helps when wake drive is working against sleep. Activating one orexin receptor helps when wake drive itself has broken down. Neither situation means that everyone with insomnia has “too much” orexin, or that everyone who feels tired has “too little.”
One more detail matters here, and it is easy to miss: FDA approval, government scheduling of a controlled substance, and actual pharmacy availability are three separate events. Oveporexton was approved by the FDA, but as of this writing it was still waiting on a scheduling decision from the Drug Enforcement Administration and was not yet available to be filled.1
Orexin is made from a gene called HCRT, which carries instructions for a larger precursor molecule. Cells cut that precursor into two active peptides, orexin-A and orexin-B, and pack them for release. When an orexin-making cell fires strongly enough, it releases these peptides near its targets and into the space nearby. There is no dedicated pump that pulls orexin back in the way there is for some other brain chemicals; the signal ends mainly through diffusion and breakdown.
Orexin-making cells are most active during engaged wakefulness and go quiet during sleep. They pick up information about the time of day, how much sleep pressure has built up, threat, reward, movement, and the body’s energy state, and their connections reach several other arousal systems: the brain’s histamine cells, its norepinephrine cells, its serotonin cells, and reward-related dopamine circuits.
A useful way to picture it: orexin acts like a stabilizer that helps a wake network hold its chosen state, the way a gyroscope resists being knocked out of position. It does not pour a single dose of “energy” into the brain. It coordinates a network of other systems and helps prevent unwanted switches between being awake, being in regular sleep, and slipping into REM-related muscle weakness at the wrong time. Where that comparison breaks down: there is no single controller of wakefulness. Circadian timing, sleep pressure, other brain chemicals, breathing, illness, and behavior all shape these state changes too.
Meet OX1R and OX2R
| Receptor or target | What it does, where it matters, and why you might care |
|---|---|
| OX1R | What it does: Usually increases the excitability of the cell it sits on. Where it matters: Arousal, reward, and stress-related circuits. Why you might care: May add to arousal, alertness to important events, and emotional response, though its distinct human role is not fully mapped out. |
| OX2R | What it does: Usually excites wake-promoting cells and helps stabilize state. Where it matters: Histamine and other wake circuits, hypothalamus, brainstem, cortex. Why you might care: The direct target for both the insomnia medicines and the new narcolepsy medicine; the main receptor tied to stable wakefulness. |
| Orexin-A and orexin-B | What it does: The two active signaling molecules; orexin-B tends to favor OX2R. Where it matters: Released widely from the lateral hypothalamus. Why you might care: Shows why one small group of cells can affect so many different circuits at once. |
| HCRT gene and prepro-orexin | What it does: The gene and precursor molecule that get cut into orexin-A and orexin-B. Where it matters: Orexin-producing hypothalamic neurons. Why you might care: Loss of these specific neurons is the defining problem in narcolepsy type 1. |
Same system, opposite treatments
An antagonist blocks a receptor from being activated. A dual orexin receptor antagonist, or DORA, blocks both OX1R and OX2R during the sleep period, which lowers wake drive and can make sleep easier for someone whose wake system is working too well at the wrong time.
An agonist activates a receptor instead. Oveporexton selectively activates OX2R. In narcolepsy type 1, it can stimulate that receptor even though most of the natural orexin signal that would normally reach it has been lost, because the cells that made it are gone.
Follow the chain for a DORA: the drug blocks OX1R and OX2R, which reduces excitation in wake circuits, which can make sleep easier, but can also bring next-day impairment or changes at the boundary of REM sleep, because the same receptors sit in more than one circuit.
Now follow oveporexton: the drug activates OX2R, which increases excitation in wake-stabilizing circuits, which can improve wakefulness and reduce sudden muscle-weakness episodes, but can also cause insomnia, urinary symptoms, or increased saliva, because OX2R sits in tissues beyond the ones doing the stabilizing work.1 A side effect from either drug shows that the drug reached its target. It does not show that a hidden imbalance was corrected.
What each medicine actually touches
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Suvorexant | What it does directly: Blocks OX1R and OX2R. Used for: Adult insomnia, trouble falling or staying asleep. Main tradeoffs: Next-day impairment, complex sleep behavior, sleep paralysis or hallucination-like experiences; contraindicated in narcolepsy. |
| Lemborexant | What it does directly: Blocks OX1R and OX2R; its main circulating breakdown product also binds both receptors. Used for: Adult insomnia, trouble falling or staying asleep. Main tradeoffs: Somnolence, next-day impairment, complex sleep behavior, a depression warning; contraindicated in narcolepsy. |
| Daridorexant | What it does directly: Blocks OX1R and OX2R. Used for: Adult insomnia, trouble falling or staying asleep. Main tradeoffs: Daytime impairment, complex sleep behavior, sleep paralysis, a depression warning; contraindicated in narcolepsy. |
| Oveporexton | What it does directly: Selectively activates OX2R. Used for: Adults with narcolepsy type 1. Main tradeoffs: Insomnia, urinary frequency or urgency, and increased saliva reported; should not be combined with strong CYP3A inhibitor drugs; not yet available to be filled at the time of writing. |
| TAK-994 (discontinued) | What it does directly: Was an OX2R agonist. Used for: Was tested in research for narcolepsy. Main tradeoffs: Development was stopped after the drug caused liver injury in trial participants; it never reached approval. |
Sharing a target does not make these medicines interchangeable. Blocking both orexin receptors for insomnia and activating one of them for narcolepsy type 1 are opposite actions used in entirely different situations.
Why an FDA approval was not the whole story
Regulatory status has more than one layer, and it is worth being precise about all of them.
FDA approved oveporexton on August 5, 2026, for adults with narcolepsy type 1.1 That approval was itself a significant event: it is the first drug of its kind approved for this condition. But approval is not the same as being able to walk into a pharmacy and fill the prescription. As of August 31, 2026, oveporexton was still awaiting a scheduling decision from the Drug Enforcement Administration, and the FDA said lawful marketing would follow that decision.1 The manufacturer’s own page described the product as coming soon, with availability expected by November. Approved is not the same as available.
There is a second, separate regulatory thread worth understanding clearly. On August 11, 2026, the DEA proposed moving suvorexant, lemborexant, and daridorexant, the three insomnia medicines, from Schedule IV to the less restrictive Schedule V.6 That was a proposal, not a final rule. As of August 31, 2026, no final rule had taken effect, and all three medicines remained Schedule IV. A proposed rule is not controlling law until it is finalized, and this distinction matters for anyone trying to understand what their prescription’s legal status actually is right now.
Can orexin be measured?
A cerebrospinal-fluid test for a substance called hypocretin-1, collected through a lumbar puncture, can support a narcolepsy type 1 evaluation in selected cases.9 It measures peptide concentration in spinal fluid. It does not directly measure how much orexin is firing in one brain region, or explain every case of sleepiness.
Overnight sleep studies, including polysomnography and a multiple sleep latency test, measure sleep physiology and how quickly someone tends to fall asleep during the day. They do not measure orexin directly. A sleep specialist puts these results together with a person’s history and other findings to reach a diagnosis.
Routine blood, urine, saliva, hair, genetic, or commercial neurotransmitter panels cannot show how much orexin is signaling in a living wake circuit. Genetic testing does not reveal a current orexin level or predict which sleep medicine will work for a given person.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: for a DORA, next-day sleepiness, dizziness, unusual dreams, sleep paralysis, or reduced alertness. For oveporexton, insomnia, more frequent or urgent urination, and increased saliva were the most commonly reported effects.1 Note the timing, how it affects your day, and any other medicines, alcohol, or cannabis you are using.
Call the prescriber or pharmacist promptly: if next-day impairment does not settle, or if you have a fall. Call for new or worsening depression, suicidal thoughts, new or distressing sleep paralysis, or hallucination-like experiences near sleep. Sudden muscle-weakness episodes, repeated urinary symptoms, a suspected drug interaction, or any dangerous sleep-related behavior also need a prompt call. Do not drive or do anything safety-sensitive while impaired.
Call Poison Control at 1-800-222-1222 for an extra dose, a mixed ingestion, an unknown amount taken, or marked sedation. Oveporexton should not be used together with strong CYP3A inhibitor drugs, so mention every medicine you take.1
Call 911 now for loss of consciousness, a seizure, severe confusion, trouble breathing, collapse, or dangerous behavior while not fully awake. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
Review your complete medicine, supplement, alcohol, and cannabis use with the prescriber, especially in pregnancy, breastfeeding, childhood, older age, lung or liver disease, depression, fall risk, or a history of substance use.
What to ask your prescriber
These are conversation starters, not instructions.
- Is the main problem falling asleep, staying asleep, excessive daytime sleepiness, or something else?
- Does this medicine block both orexin receptors, or activate one of them?
- Which early effects are likely to settle on their own, and which need a prompt call?
- What interactions matter with alcohol, cannabis, other sleep medicines, or drugs that affect CYP3A?
- Could breathing problems, fall risk, depression, liver disease, or a substance-use history change what is safe for me?
- What should I do if I miss a dose?
- Could stopping this medicine suddenly cause my original sleep problem to come back?
- If we are discussing oveporexton, has DEA scheduling happened yet, and can it actually be filled?
Bottom line
Orexin holds wakefulness steady, and the same receptor pair supports opposite treatments because insomnia and narcolepsy type 1 are opposite problems, not points on one dial. Your brain is not a gas tank that runs low or full on one wake chemical, and orexin’s two-sided story is a clear example of why. Ask what a sleep medicine touches directly, and if it is a newly approved drug, ask specifically whether it is actually available yet, not just approved.
Two related signals worth knowing: adenosine builds the sleep pressure that orexin works against during the day, and histamine is another wake-promoting signal that many sedating psychiatric medicines also touch.
Frequently asked questions
Does daytime tiredness mean my orexin is low?
No. Tiredness can come from too little sleep, sleep apnea, circadian timing, anemia, infection, pain, depression, medication, alcohol, or cannabis, among other causes. Narcolepsy type 1 is diagnosed through a defined sleep-medicine evaluation, not from tiredness alone.
Does insomnia mean my orexin is high?
No. A medicine that blocks orexin can help with sleep without proving that excess orexin caused the problem in the first place.
Are these insomnia medicines just another kind of benzodiazepine?
No. They block orexin receptors. Benzodiazepines work on a completely different system, the GABA-A receptor. Both can impair alertness, but their mechanisms, interactions, and safety profiles differ.
Is oveporexton a stimulant like amphetamine?
No. Oveporexton directly activates OX2R. Amphetamine-type stimulants work mainly through different brain-chemical transporters. Both may support wakefulness in some settings, but a shared outcome does not mean a shared mechanism.
Why are the insomnia medicines contraindicated in narcolepsy?
Narcolepsy type 1 already involves a loss of orexin’s own wake-stabilizing signal. Blocking the receptor further could worsen the exact system the condition has already weakened.
Does an FDA approval mean I can fill the prescription today?
Not necessarily. Scheduling and distribution decisions can still be pending after approval, as they were for oveporexton at the time of this writing.
Does one earlier failed narcolepsy drug mean the new one is unsafe?
No. TAK-994’s liver injury was an important warning tied to that specific molecule.8 It justifies careful, molecule-specific safety review, but it does not establish the same risk for a different drug like oveporexton, which underwent its own separate safety evaluation.
Does a proposed DEA rule change my medicine’s legal schedule right now?
No. A proposal is not the same as a final rule. At the time of this writing, the three insomnia medicines discussed here remained in their existing legal schedule.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- What Caffeine Blocks, and What It Cannot Undo
- The Allergy Chemical That Keeps You Awake
- Melatonin Is a Clock, Not a Sleeping Pill
References
1. FDA. Approval of Orzeyful (oveporexton) for adults with narcolepsy type 1. August 5, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
2. FDA. Novel Drug Approvals for 2026. Accessed August 31, 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
3. Suvorexant (Belsomra) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951
4. Lemborexant (Dayvigo) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd
5. Daridorexant (Quviviq) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a2d1503-b816-40c9-9fac-7e03c5a3bcef
6. DEA. Proposed rescheduling of suvorexant, lemborexant, and daridorexant. Federal Register. August 11, 2026. https://www.federalregister.gov/documents/2026/08/11/2026-16375/schedules-of-controlled-substances-rescheduling-of-suvorexant-lemborexant-and-daridorexant-from
7. Dauvilliers Y, et al. Oveporexton phase 2 trial. N Engl J Med. 2025. PMID: 40367374
8. Dauvilliers Y, Mignot E, et al. Oral orexin receptor 2 agonist in narcolepsy type 1; TAK-994 development ended after hepatic injury. N Engl J Med. 2023. PMID: 37494485
9. Mignot E, et al. CSF hypocretin in narcolepsy. Arch Neurol. 2002. PMID: 12374492
10. Lin L, et al. HCRTR2 mutation in canine narcolepsy. Cell. 1999. PMID: 10458611
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, or change a medicine because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.